Kanserde MikroRNA’lar ve İlaç Yanıtı

Çiğdem Aydın Acar; Şükriye Yeşilot

doi:10.17343/sdutfd.345988

Kanserde MikroRNA’lar ve İlaç Yanıtı

Öz

MikroRNA’lar (miRNA), hedef gen ekspresyonunu post-transkripsiyonel olarak kontrol eden küçük kodlanmayan RNA molekülleridir. miRNA’ların hedef genleri baskılayarak büyüme, gelişme, farklılaşma ve hücre ölümü süreçlerinin düzenlenmesinde önemli rol oynadığına dair çok sayıda çalışma mevcuttur. MiRNA’ların düzenlenmesindeki bozuklukların kanser ile bağlantılı olması bu bağlamda şaşırtıcı değildir. Buna ek olarak, miRNA ifadelerinin ilaçlar tarafından değiştirilebildiği ve miRNA'ların kanser tedavisinde ilaç metabolizmasının düzenlenmesini ve toksisiteyi etkilediği bildirilmiştir. İlaç yanıtı, hem genetik hem de çevresel faktörler tarafından düzenlenen karmaşık bir süreçtir. Bugüne kadar farklı miRNA'ların birçok antikanser terapiye karşı duyarlılığı öngördüğü veya etkilediği bulunmuştur. Bu derleme de, miRNA biyojenezini takiben, miRNA'ların kanser, ilaç yanıtı ve antikanser tedavileri üzerindeki potansiyel rolünü ortaya koyan mevcut çalışmaların tartışılması amaçlanmıştır.

Anahtar Kelimeler

MikroRNA; Kanser; İlaç yanıtı

Kaynakça

1. Kusenda B, Mraz M, Mayer J, Pospisilova S. MicroRNA biogenesis, functionality and cancer relevance. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006; 150: 205–15.
2. Narry KV. Small RNAs: Classification, Biogenesis, and Function. Mol Cells 2005; 19(1):1-15.
3. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNAs host genes and transcription units. Genome Res 2004; 14: 1902–1910
4. Lee RC, Feinbaum RL, Ambros V. The C. Elegans heterochronic gene Lin-4 encodes small RNAs with antisense complementarity to Lin-14. Cell 1993; 75 (5): 843–845
5. http://www.mirbase.org
6. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004;23(20):4051-60.
7. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004;10(12):1957-66.
8. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rådmark O, Kim S, Kim VN. The nuclear RNase Drosha initiates microRNA processing. Nature 2003;425(6956):415-9.

9. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of premicroRNA precursors. Genes Dev 2003;17(24):3011-6.
10. Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev 2001;15(20):2654-9.
11. Lund E, Güttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science 2004; 303(5654):95–8.
12. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007;23:175-205.
13. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000; 404 (6775):293–6.
14. Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003;115(2):199-208.
15. Lee S, Choi E, Cha M, Hwang KC. Implications of MicroRNAs in the Vascular Homeostasis and Remodeling, Muscle Cell and Tissue 2015. https://www.intechopen.com/books/muscle-cell-and-tissue/implications-of-micrornas-in-the-vascular-homeostasis-and-remodeling
16. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2):281-297.
17. Koturbash I, Beland FA, Pogribny IP. Role of microRNAs in the regulation of drug metabolizing and transporting genes and the response to environmental toxicants. Expert Opin Drug Metab Toxicol 2012; 8(5): 597–606.
18. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev Genet 2004; 5(7): 522–531.
19. Wu L, Fan J, Belasco JG. MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci USA 2006; 103(11):4034–4039.
20. Karagün BŞ, Bülen, Antmen B, Şaşmaz İ, Kılınç Y. Mikro RNA ve Kanser. Türk Klinik Biyokimya Derg 2014; 12(1): 45-56.
21. Sun W, Li YSJ, Huang HD, Shyy JYJ, Chien S. MicroRNA: A Master Regulator of Cellular Processes for Bioengineering Systems. Annu Rev Biomed Eng 2010; 12: 1-27.
22. Pillai RS. MicroRNA function: multiple mechanisms fora tiny RNA. RNA 2005;11(12):1753-61.
23. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006, 66:7390-7394.
24. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massagué J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008;451:147-152.
25. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H. MicroRNA-21 (miR-21) posttranscriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2007; 27:2128-2136.
26. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008;10:202-210.
27. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9:189-198.
28. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99(24):15524-9.
29. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:13944-13949.
30. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. Cell 2005;120(5):635–647.
31. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64(11); 3753–3756.
32. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353(17):1793–1801.
33. Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A. High expression of precursor microRNA-155/ BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 2004;39:167–169.
34. Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 2005; 207(2): 243–249.
35. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65(16):7065–7070.
36. Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys Res Commun 2005;334(4):1351– 1358.
37. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103(7): 2257–2261.
38. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65(14):6029–6033.
39. Le Quesne J, Caldas C. Micro-RNAs and breast cancer. Moleculer Oncology 2010; 4(3): 230-41.
40. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005; 102(52): 19075-80.
41. Sevli S, Uzumcu A, Solak M, Ittmann M, Ozen M. The function microRNAs, small potent molecules in human prostate cancer. Prostate Cancer Prostatic Dis 2010; 13(3): 208-17.
42. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65(21): 9628-32.
43. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25(17): 2537-45.
44. Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Can cer Res 2003;1(12): 882- 91
45. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences USA 2008;105(30):10513-10518.
46. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecologic Oncology 2008; 110(1):13-21.
47. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research 2008;18(10):997-1006.
48. Garofalo M, Condorelli G, Croce CM. MicroRNAs in diseases and drug response. Current opinion in pharmacology 2008;8(5):661–667.
49. Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, Liu CG, Croce CM, Condorelli G. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008; 27(27):3845-3855.
50. Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res 2007;67(19):8994-9000.
51. Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z, Liu CG, Reinhold W, Lorenzi PL, Kaldjian EP et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 2007; 6(5):1483-1491.
52. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino JR. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci USA 2007;104(33):13513-13518.
53. Baer-Dubowska W, Majchrzak-Celinska A, Cichocki M. Pharmocoepigenetics: A new approach to predicting individual drug responses and targeting new drugs. Pharmacol Rep 2011; 63(2):293–304.
54. Nakajima M, Yokoi T. MicroRNAs from biology to future pharmacotherapy: Regulation of cytochrome P450s and nuclear receptors. Pharmacol Ther 2011; 131(3): 330–337.
55. Gomez A, Ingelman-Sundberg M. Epigenetic and microrna-dependent control of cytochrome p450 expression: A gap between DNA and protein. Pharmacogenomics 2009; 10(7):1067–1076.
56. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T. Microrna regulates the expression of human cytochrome p450 1b1. Cancer Res 2006; 66(18):9090–9098.
57. Kalscheuer S, Zhang X, Zeng Y, Upadhyaya P. Differential expression of micrornas in early-stage neoplastic transformation in the lungs of f344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 2008; 29(12):2394–2399.
58. Zhang W, Dolan ME. Emerging role of microRNAs in drug response. Curr Opin Mol Ther 2010;12(6): 695–702.
59. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM. Role of microrna mir-27a and mir-451 in the regulation of mdr1/p-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008; 76(5):582–588.
60. Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H. A functional polymorphism in the mir-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 2008; 29(10):1963–1966.
61. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P, Ghoshal K. Microrna-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009; 284(46):32015–32027.
62. Kotani A, Ha D, Hsieh J, Rao PK, Schotte D, den Boer ML, Armstrong SA, Lodish HF. Mir-128b is a potent glucocorticoid sensitizer in mll-af4 acute lymphocytic leukemia cells and exerts cooperative effects with mir-221. Blood 2009; 114(19):4169–4178.
63. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A et al. Mir-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009; 15(16):5060–5072. 64. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S. Microrna-221/222 confers tamoxifen resistance in breast cancer by targeting p27kip1. J Biol Chem 2008; 283(44):29897–29903.
65. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M, Ju J. Non-coding micrornas hsa-let-7g and hsa-mir-181b are associated with chemoresponse to s-1 in colon cancer. Cancer genomics & proteomics 2006; 3(5):317–324.
66. Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM. Microrna-143 reduces viability and increases sensitivity to 5-fluorouracil in hct116 human colorectal cancer cells. The FEBS journal 2009; 276(22):6689–6700.
67. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of micrornas in drug resistant ovarian cancer cells. Gynecologic oncology 2008; 111(3):478–486.
68. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K et al. Microrna microarray identifies let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008; 68(24):10307–10314.
69. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. Ras is regulated by the let-7 microrna family. Cell 2005; 120(5):635–647.
70. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ. Micrornas as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007; 67(23): 11111–11116.
71. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX et al. Microrna expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361(15):1437–1447.
72. Hummel R, Hussey DJ, Haier J. Micrornas: Predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010; 46(2):298–311.
73. Zheng T, Wang J, Chen X, Liu L. Role of microrna in anticancer drug resistance. Int J Cancer 2010;126(1):2–10.
74. Wang V, Wu W. Microrna-based therapeutics for cancer. BioDrugs 2009;23(1):15–23.

Ayrıntılar

Birincil Dil

Türkçe

Konular

Klinik Tıp Bilimleri

Bölüm

Derleme

Yazarlar

Çiğdem Aydın Acar
MEHMET AKİF ERSOY ÜNİVERSİTESİ
Türkiye

Şükriye Yeşilot
MEHMET AKİF ERSOY ÜNİVERSİTESİ
Türkiye

Yayımlanma Tarihi

1 Aralık 2018

Gönderilme Tarihi

23 Ekim 2017

Kabul Tarihi

22 Ocak 2018

Yayımlandığı Sayı

Yıl 2018 Cilt: 25 Sayı: 4

DOI

https://doi.org/10.17343/sdutfd.345988

IZ

https://izlik.org/JA54LZ77NS

Kaynak Göster

RIS / Bibtex

APA

Aydın Acar, Ç., & Yeşilot, Ş. (2018). Kanserde MikroRNA’lar ve İlaç Yanıtı. Medical Journal of Süleyman Demirel University, 25(4), 498-507. https://doi.org/10.17343/sdutfd.345988

AMA

1.Aydın Acar Ç, Yeşilot Ş. Kanserde MikroRNA’lar ve İlaç Yanıtı. SDÜ Tıp Fak Derg. 2018;25(4):498-507. doi:10.17343/sdutfd.345988

Chicago

Aydın Acar, Çiğdem, ve Şükriye Yeşilot. 2018. “Kanserde MikroRNA’lar ve İlaç Yanıtı”. Medical Journal of Süleyman Demirel University 25 (4): 498-507. https://doi.org/10.17343/sdutfd.345988.

EndNote

Aydın Acar Ç, Yeşilot Ş (01 Aralık 2018) Kanserde MikroRNA’lar ve İlaç Yanıtı. Medical Journal of Süleyman Demirel University 25 4 498–507.

IEEE

[1]Ç. Aydın Acar ve Ş. Yeşilot, “Kanserde MikroRNA’lar ve İlaç Yanıtı”, SDÜ Tıp Fak Derg, c. 25, sy 4, ss. 498–507, Ara. 2018, doi: 10.17343/sdutfd.345988.

ISNAD

Aydın Acar, Çiğdem - Yeşilot, Şükriye. “Kanserde MikroRNA’lar ve İlaç Yanıtı”. Medical Journal of Süleyman Demirel University 25/4 (01 Aralık 2018): 498-507. https://doi.org/10.17343/sdutfd.345988.

JAMA

1.Aydın Acar Ç, Yeşilot Ş. Kanserde MikroRNA’lar ve İlaç Yanıtı. SDÜ Tıp Fak Derg. 2018;25:498–507.

MLA

Aydın Acar, Çiğdem, ve Şükriye Yeşilot. “Kanserde MikroRNA’lar ve İlaç Yanıtı”. Medical Journal of Süleyman Demirel University, c. 25, sy 4, Aralık 2018, ss. 498-07, doi:10.17343/sdutfd.345988.

Vancouver

1.Çiğdem Aydın Acar, Şükriye Yeşilot. Kanserde MikroRNA’lar ve İlaç Yanıtı. SDÜ Tıp Fak Derg. 01 Aralık 2018;25(4):498-507. doi:10.17343/sdutfd.345988